Brief Correspondence – Benign Prostatic ObstructionClinical Efficacy of Silodosin in Patients with Severe Lower Urinary Tract Symptoms Related to Benign Prostatic Obstruction: A Pooled Analysis of Phase 3 and 4 Trials
References (10)
- et al.
Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. European Silodosin Study Group
Eur Urol
(2011) - et al.
One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice
Urology
(2000) - et al.
Relationship between lifestyle and health factors and severe lower urinary tract symptoms (LUTS) in 106,435 middle-aged and older Australian men: population-based study
PLoS One
(2014) - et al.
Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study
BMC Urol
(2018) - et al.
Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: a European phase IV clinical study (SiRE study)
Int J Urol
(2016)
There are more references available in the full text version of this article.
Cited by (3)
Preserving Sexual Function in Men With LUTS Secondary to Large Prostates
2022, Journal of Sexual MedicineEvolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review
2022, Drug Design, Development and Therapy
© 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.